Role of thrombospondin 1 in liver diseases

Hepatology Research

Volumn 47, Issue 2, 2017, Pages 186-193

  Li, Yanzhang ^a,b   Turpin, Courtney P ^a   Wang, Shuxia ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b HENAN UNIVERSITY   (China)

Author keywords

angiogenesis; liver cancer; liver fibrosis; NAFLD; TGF ; TSP1

Indexed keywords

THROMBOSPONDIN 1;

CANCER GROWTH; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 84992109304     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12787     Document Type: Review

References (93)

1. Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol 2004; 36: 961–8.
2. Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin-1. Matrix Biol 2000; 19: 597–614.
3. Lawler J. The functions of thrombospondin-1 and-2. Curr Opin Cell Biol 2000; 12: 634–640.
4. Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest 2001; 107: 929–934.
5. Murphy-Ullrich JE, Iozzo RV. Thrombospondins in physiology and disease: new tricks for old dogs. Matrix Biol 2012; 31: 152–4.
6. Esemuede N, Lee T, Pierre-Paul D, Sumpio BE, Gahtan V. The role of thrombospondin-1 in human disease. J Surg Res 2004; 122: 135–142.
7. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002; 6: 1–12.
8. Isenberg JS, Frazier WA, Roberts DD. Thrombospondin-1: a physiological regulator of nitric oxide signaling. Cell Mol Life Sci 2008; 65: 728–742.
9. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2009; 2:.re3
10. Li Y, Qi X, Tong X, Wang S. Thrombospondin 1 activates the macrophage Toll-like receptor 4 pathway. Cell Mol Immunol 2013; 19: 32.
11. Maimaitiyiming H, Zhou Q, Wang S. Thrombospondin 1 deficiency ameliorates the development of adriamycin-induced proteinuric kidney disease. PLoS One 2016; 11:.e0156144
12. Isenberg JS, Jia Y, Fukuyama J, Switzer CH, Wink DA, Roberts DD. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem 2007; 282: 15404–415.
13. Lawler PR, Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med 2012; 2: a006627.
14. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6: 41–48.
15. Roberts W, Magwenzi S, Aburima A, Naseem KM. Thrombospondin-1 induces platelet activation through CD36-dependent inhibition of the cAMP/protein kinase A signaling cascade. Blood 2010; 116: 4297–4306.
16. Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 2001; 11: 130–5.
17. Oldenborg PA. CD47: a cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease. ISRN Hematol 2013; 2013: 614619.
18. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 2006; 281: 26069–080.
19. Isenberg JS, Shiva S, Gladwin M. Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation. Nitric Oxide 2009; 21: 52–62.
20. Rogers NM, Thomson AW, Isenberg JS. Activation of parenchymal CD47 promotes renal ischemia–reperfusion injury. J Am Soc Nephrol 2012; 23: 1538–50.
21. Isenberg JS, Romeo MJ, Yu C et al. Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood 2008; 111: 613–623.
22. Liu Z, Morgan S, Ren J et al. Thrombospondin-1 (TSP1) contributes to the development of vascular inflammation by regulating monocytic cell motility in mouse models of abdominal aortic aneurysm. Circ Res 2015; 117: 129–141.
23. Schultz-Cherry S, Chen H, Mosher DF et al. Regulation of transforming growth factor-β activation by discrete sequences of thrombospondin 1. J Biol Chem 1995; 270: 7304–10.
24. Wang S, Shiva S, Poczatek MH, Darley-Usmar V, Murphy-Ullrich JE. Nitric oxide and cGMP-dependent protein kinase regulation of glucose-mediated thrombospondin 1-dependent transforming growth factor-β activation in mesangial cells. J Biol Chem 2002; 277: 9880–88.
25. Lu A, Miao M, Schoeb TR, Agarwal A, Murphy-Ullrich JE. Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol 2011; 178: 2573–86.
26. Wang S, Skorczewski J, Feng X, Mei L, Murphy-Ullrich JE. Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-β activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2. J Biol Chem 2004; 279: 34 311– 322.
27. Schultz-Cherry S, Murphy-Ullrich JE. Thrombospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism. J Cell Biol 1993; 122: 923–932.
28. Soto-Pantoja DR, Shih HB, Maxhimer JB et al. Thrombospondin-1 and CD47 signaling regulate healing of thermal injury in mice. Matrix Biol 2014; 37: 25–34.
29. Xiao ZY, Banan B, Jia J et al. CD47 blockade reduces ischemia/reperfusion injury and improves survival in a rat liver transplantation model. Liver Transpl 2015; 21: 468–477.
30. Rogers NM, Zhang ZJ, Wang JJ, Thomson AW, Isenberg JS. CD47 regulates renal tubular epithelial cell self-renewal and proliferation following renal ischemia reperfusion. Kidney Int 2016.
31. Wong SY, Purdie AT, Han P. Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study. Am J Pathol 1992; 140: 1473–82.
32. Ortiz-Masia D, Diez I, Calatayud S et al. Induction of CD36 and thrombospondin-1 in macrophages by hypoxia-inducible factor 1 and its relevance in the inflammatory process. PLoS One 2012; 7:.e48535
33. Li Y, Tong X, Rumala C, Clemons K, Wang S. Thrombospondin1 deficiency reduces obesity-associated inflammation and improves insulin sensitivity in a diet-induced obese mouse model. PLoS One 2011; 6:.e26656
34. Rogers NM, Sharifi-Sanjani M, Csanyi G, Pagano PJ, Isenberg JS. Thrombospondin-1 and CD47 regulation of cardiac, pulmonary and vascular responses in health and disease. Matrix Biol 2014; 37: 92–101.
35. Zeisberg M, Tampe B, LeBleu V, Tampe D, Zeisberg EM, Kalluri R. Thrombospondin-1 deficiency causes a shift from fibroproliferative to inflammatory kidney disease and delays onset of renal failure. Am J Pathol 2014; 184: 2687–98.
36. Fairaq A, Goc A, Artham S, Sabbineni H, Somanath PR. TNFα induces inflammatory stress response in microvascular endothelial cells via Akt- and p38 MAP kinase-mediated thrombospondin-1 expression. Mol Cell Biochem 2015; 406: 227–236.
37. Soriano-Romani L, Garcia-Posadas L, Lopez-Garcia A, Paraoan L, Diebold Y. Thrombospondin-1 induces differential response in human corneal and conjunctival epithelial cells lines under in vitro inflammatory and apoptotic conditions. Exp Eye Res 2015; 134: 1–14.
38. Xu L, Choi TH, Kim S et al. Anthocyanins from black soybean seed coat enhance wound healing. Ann Plast Surg 2013; 71: 415–420.
39. Iruela-Arispe ML, Liska DJ, Sage EH, Bornstein P. Differential expression of thrombospondin 1, 2, and 3 during murine development. Dev Dyn 1993; 197: 40–56.
40. Lawler J, Sunday M, Thibert V et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 1998; 101: 982–992.
41. El-Youssef M, Mu Y, Huang L, Stellmach V, Crawford SE. Increased expression of transforming growth factor-β1 and thrombospondin-1 in congenital hepatic fibrosis: possible role of the hepatic stellate cell. J Pediatr Gastroenterol Nutr 1999; 28: 386–392.
42. Chavez-Tapia NC, Rosso N, Tiribelli C. Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterol 2012; 12: 20.
43. Hayashi H, Sakai K, Baba H, Sakai T. Thrombospondin-1 is a novel negative regulator of liver regeneration after partial hepatectomy through transforming growth factor-β1 activation in mice. Hepatology 2012; 55: 1562–73.
44. Smalling RL, Delker DA, Zhang Y et al. Genome-wide transcriptome analysis identifies novel gene signatures implicated in human chronic liver disease. Am J Physiol Gastrointest Liver Physiol 2013; 305: G364–G374.
45. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10: 686–690.
46. Bige N, Shweke N, Benhassine S et al. Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction. Kidney Int 2012; 81: 1226–38.
47. McMorrow JP, Crean D, Gogarty M et al. Tumor necrosis factor inhibition modulates thrombospondin-1 expression in human inflammatory joint disease through altered NR4A2 activity. Am J Pathol 2013; 183: 1243–57.
48. Contreras-Ruiz L, Regenfuss B, Mir FA, Kearns J, Masli S. Conjunctival inflammation in thrombospondin-1 deficient mouse model of Sjogren's syndrome. PLoS One 2013; 8:.e75937
49. McMaken S, Exline MC, Mehta P et al. Thrombospondin-1 contributes to mortality in murine sepsis through effects on innate immunity. PLoS One 2011; 6:.e19654
50. Yang K, Vega JL, Hadzipasic M et al. Deficiency of thrombospondin-1 reduces Th17 differentiation and attenuates experimental autoimmune encephalomyelitis. J Autoimmun 2009; 32: 94–103.
51. Rico MC, Manns JM, Driban JB, Uknis AB, Kunapuli SP, Dela Cadena RA. Thrombospondin-1 and transforming growth factor β are pro-inflammatory molecules in rheumatoid arthritis. Transl Res 2008; 152: 95–98.
52. Lopez-Dee Z, Pidcock K, Gutierrez LS. Thrombospondin-1: multiple paths to inflammation. Mediators Inflamm 2011; 2011: 296069.
53. Hiscott P, Armstrong D, Batterbury M, Kaye S. Repair in avascular tissues: fibrosis in the transparent structures of the eye and thrombospondin 1. Histol Histopathol 1999; 14: 1309–20.
54. Varma V, Yao-Borengasser A, Bodles AM et al. Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance. Diabetes 2008; 57: 432–9.
55. Inoue M, Jiang Y, Barnes RH 2nd et al. Thrombospondin 1 mediates HFD-induced muscle fibrosis and insulin resistance in male mice. Endocrinology 2013; 18: 18.
56. Kong P, Gonzalez-Quesada C, Li N, Cavalera M, Lee DW, Frangogiannis NG. Thrombospondin-1 regulates adiposity and metabolic dysfunction in diet-induced obesity enhancing adipose inflammation and stimulating adipocyte proliferation. Am J Physiol Endocrinol Metab 2013; 305: E439–E450.
57. Cui W, Maimaitiyiming H, Qi X, Norman H, Wang S. Thrombospondin 1 mediates renal dysfunction in a mouse model of high-fat diet-induced obesity. Am J Physiol Renal Physiol 2013; 305: F871–F880.
58. Wu H, Jin M, Han D et al. Protective effects of aerobic swimming training on high-fat diet induced nonalcoholic fatty liver disease: regulation of lipid metabolism via PANDER-AKT pathway. Biochem Biophys Res Commun 2015; 458: 862–8.
59. Chen RJ, Wu HH, Wang YJ. Strategies to prevent and reverse liver fibrosis in humans and laboratory animals. Arch Toxicol 2015; 89: 1727–50.
60. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655–69.
61. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 2014; 14: 181–194.
62. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007; 117: 539–548.
63. Fabregat I, Moreno-Caceres J, Sanchez A et al. TGF-β signaling and liver disease. FEBS J 2016; 12: 2219–32.
64. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFβ activation. J Cell Sci 2003; 116: 217–224.
65. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-β by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000; 11: 59–69.
66. Daniel C, Schaub K, Amann K, Lawler J, Hugo C. Thrombospondin-1 is an endogenous activator of TGF-β in experimental diabetic nephropathy in vivo. Diabetes 2007; 56: 2982–89.
67. Sweetwyne MT, Murphy-Ullrich JE. Thrombospondin1 in tissue repair and fibrosis: TGF-beta-dependent and independent mechanisms. Matrix Biol 2012; 31: 178–186.
68. Belmadani S, Bernal J, Wei CC et al. A thrombospondin-1 antagonist of transforming growth factor-β activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II. Am J Pathol 2007; 171: 777–789.
69. Daniel C, Takabatake Y, Mizui M et al. Antisense oligonucleotides against thrombospondin-1 inhibit activation of TGF-β in fibrotic renal disease in the rat in vivo. Am J Pathol 2003; 163: 1185–1192.
70. Kondou H, Mushiake S, Etani Y, Miyoshi Y, Michigami T, Ozono K. A blocking peptide for transforming growth factor-β1 activation prevents hepatic fibrosis in vivo. J Hepatol 2003; 39: 742–8.
71. Breitkopf K, Sawitza I, Westhoff JH, Wickert L, Dooley S, Gressner AM. Thrombospondin 1 acts as a strong promoter of transforming growth factor β effects via two distinct mechanisms in hepatic stellate cells. Gut 2005; 54: 673–681.
72. Myung SJ, Yoon JH, Gwak GY et al. Bile acid-mediated thrombospondin-1 induction in hepatocytes leads to transforming growth factor-β-dependent hepatic stellate cell activation. Biochem Biophys Res Commun 2007; 353: 1091–96.
73. Benzoubir N, Lejamtel C, Battaglia S et al. HCV core-mediated activation of latent TGF-beta via thrombospondin drives the crosstalk between hepatocytes and stromal environment. J Hepatol 2013; 59: 1160–68.
74. Bornstein P. Thrombospondins function as regulators of angiogenesis. J Cell Commun Signal 2009; 3: 189–200.
75. Elpek GO. Angiogenesis and liver fibrosis. World J Hepatol 2015; 7: 377–391.
76. Kaur S, Anita K. Angiogenesis in liver regeneration and fibrosis: “a double-edged sword”. Hepatol Int 2013; 7: 959–968.
77. Valfre di Bonzo L, Novo E, Cannito S et al. Angiogenesis and liver fibrogenesis. Histol Histopathol 2009; 24: 1323–41.
78. Park S, Kim JW, Kim JH, Lim CW, Kim B. Differential roles of angiogenesis in the induction of fibrogenesis and the resolution of fibrosis in liver. Biol Pharm Bull 2015; 38: 980–5.
79. Elpek GO, Gokhan GA, Bozova S. Thrombospondin-1 expression correlates with angiogenesis in experimental cirrhosis. World J Gastroenterol 2008; 14: 2213–17.
80. Venkatraman L, Tucker-Kellogg L. The CD47-binding peptide of thrombospondin-1 induces defenestration of liver sinusoidal endothelial cells. Liver Int 2013; 33: 1386–97.
81. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.
82. Hayashi K, Kurohiji T, Shirouzu K. Localization of thrombospondin in hepatocellular carcinoma. Hepatology 1997; 25: 569–574.
83. Yerian LM, Anders RA, Tretiakova M, Hart J. Caveolin and thrombospondin expression during hepatocellular carcinogenesis. Am J Surg Pathol 2004; 28: 357–364.
84. Poon RT, Chung KK, Cheung ST et al. Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 4150–57.
85. Kasper HU, Ebert M, Malfertheiner P, Roessner A, Kirkpatrick CJ, Wolf HK. Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. Virchows Arch 2001; 438: 116–120.
86. Yamashita Y, Kurohiji T, Tuszynski GP, Sakai T, Shirakusa T. Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer 1998; 82: 632–8.
87. Straume O, Akslen LA. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001; 159: 223–235.
88. Grossfeld GD, Ginsberg DA, Stein JP et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997; 89: 219–227.
89. Fontanini G, Boldrini L, Calcinai A et al. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density. Clin Cancer Res 1999; 5: 155–161.
90. Lee TK, Cheung VC, Lu P et al. Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 2014; 60: 179–191.
91. Chen R, Tan Y, Wang M et al. Development of glycoprotein capture-based label-free method for the high-throughput screening of differential glycoproteins in hepatocellular carcinoma. Mol Cell Proteomics 2011; 10:.M110.006445
92. Tamori A, Murakami Y, Kubo S et al. MicroRNA expression in hepatocellular carcinoma after the eradication of chronic hepatitis virus C infection using interferon therapy. Hepatol Res 2016; 46: E26–35.
93. Wada H, Nagano H, Yamamoto H et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1α. Liver Int 2006; 26: 414–423.